Your session is about to expire
← Back to Search
Procedure
Trigger Point Injections for Myofascial Pain
Phase 2
Waitlist Available
Led By Mohab Ibrahim, Md., Ph.D
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosis of myofascial pain
Failed conservative therapy or unable to participate in physical therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 days
Awards & highlights
Study Summary
This trial will help to determine how many needle passes are necessary to achieve pain control for myofascial pain patients.
Who is the study for?
This trial is for English-speaking individuals with myofascial pain who haven't found relief through conservative treatments or can't do physical therapy. It's not suitable for those with serious mental illnesses that affect pain perception or conditions causing widespread pain.Check my eligibility
What is being tested?
The study tests how many needle passes in trigger point injections (using lidocaine and bupivacaine) are best for relieving chronic muscle pain. Participants will be randomly assigned to receive either 2, 10, or 20 needle passes at a clinic in Tucson, Arizona.See study design
What are the potential side effects?
Possible side effects from the injections may include temporary discomfort at the injection site, bruising, bleeding, allergic reactions to the anesthetics used (lidocaine and bupivacaine), and rarely nerve damage.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with muscle pain.
Select...
Physical therapy did not work for me or I cannot do it.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 60 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in pain intensity
Secondary outcome measures
Change in Sleep patterns
Perceived Subjective Changes in the Ability to Work, Do Chores, and Exercise.
Trial Design
3Treatment groups
Active Control
Group I: One to two needle passesActive Control1 Intervention
Receive 1-2 needle passes for needling at each trigger point
Group II: Ten needle passesActive Control1 Intervention
Receive 10 needle passes for needling at each trigger point
Group III: Twenty needle passesActive Control1 Intervention
Receive 20 needle passes for needling at each trigger point
Find a Location
Who is running the clinical trial?
University of ArizonaLead Sponsor
518 Previous Clinical Trials
148,303 Total Patients Enrolled
Mohab Ibrahim, Md., Ph.DPrincipal InvestigatorUniversity of Arizona
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have a history of conditions that cause widespread pain.I have a mental illness that affects my ability to feel changes in pain.I have been diagnosed with muscle pain.Physical therapy did not work for me or I cannot do it.
Research Study Groups:
This trial has the following groups:- Group 1: One to two needle passes
- Group 2: Ten needle passes
- Group 3: Twenty needle passes
Awards:
This trial has 3 awards, including:- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Myofascial Pain Syndrome Patient Testimony for trial: Trial Name: NCT04732507 — Phase 2
Share this study with friends
Copy Link
Messenger